{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:41:36Z","timestamp":1791391296585,"version":"4.3.3"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["B180"],"award-info":[{"award-number":["B180"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ctrv.2024.102862","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T04:09:55Z","timestamp":1735013395000},"page":"102862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-9985","authenticated-orcid":false,"given":"Sofia","family":"Georgopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Droney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorni Priya","family":"Jaganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aislinn Macklin-","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctrv.2024.102862_b0005","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2018.11.018","article-title":"An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system","volume":"107","author":"Larkin","year":"2019","journal-title":"Eur J Cancer"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102862_b0020","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600\u2013mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102862_b0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2016.10.009","article-title":"Adjuvant ipilimumab in stage III melanoma: new landscape, new questions","volume":"69","author":"Eggermont","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102862_b0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.it.2016.01.001","article-title":"T cell vaccinology: beyond the reflection of infectious responses","volume":"37","author":"Pennock","year":"2016","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000585","article-title":"Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma","volume":"5","author":"Favara","year":"2020","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102862_b0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0060","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102862_b0065","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102862_b0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0075","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.13365","article-title":"The adverse events associated with combination immunotherapy in cancers: Challenges and chances","volume":"16","author":"Zhuo","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102862_b0080","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/cam4.2940","article-title":"Cancer patients\u2019 experiences with immune checkpoint modulators: a qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102862_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.710518","article-title":"Key determinants of health-related quality of life among advanced lung Cancer patients: a qualitative study in Belgium and Italy","volume":"12","author":"Janssens","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102862_b0090","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","article-title":"The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)","volume":"26","author":"Al-Batran","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0095","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fonc.2020.00864","article-title":"Breast cancer survivorship, quality of life, and late toxicities","volume":"10","author":"Nardin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0100","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O\u2019Reilly","year":"2020","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102862_b0105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctrv.2024.102862_b0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0115","doi-asserted-by":"crossref","first-page":"W-65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2024.102862_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.ctrv.2024.102862_b0125","doi-asserted-by":"crossref","unstructured":"Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021 Mar 29;372.","DOI":"10.1136\/bmj.n71"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0130","first-page":"285","article-title":"The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers","volume":"34","author":"Hong","year":"2018","journal-title":"Educ Inf"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102862_b0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jpainsymman.2022.02.013","article-title":"Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice","volume":"63","author":"Koldenhof","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0275","doi-asserted-by":"crossref","first-page":"14367","DOI":"10.1038\/s41598-022-16588-3","article-title":"Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II clinical trial","volume":"12","author":"Mendoza","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102862_b0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.08.004","article-title":"Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: health-related quality of life from the randomized phase 3 KEYNOTE-716 study","volume":"176","author":"Khattak","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102862_b0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102862_b0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2023.03.014","article-title":"Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial","volume":"187","author":"Schadendorf","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-022-00414-5","article-title":"Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial","volume":"6","author":"Tolstrup","year":"2022","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102862_b0160","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102862_b0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cllc.2021.02.010","article-title":"Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non\u2013small-cell lung cancer (MYSTIC)","volume":"22","author":"Garon","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.34477","article-title":"Patient\u2010reported outcomes with cemiplimab monotherapy for first\u2010line treatment of advanced non\u2013small cell lung cancer with PD\u2010L1 of\u2265 50%: The EMPOWER\u2010Lung 1 study","volume":"129","author":"G\u00fcm\u00fc\u015f","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102862_b0180","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-19-2838","article-title":"Patient-reported outcomes from the phase III Randomized IMmotion151 Trial: Atezolizumab+ Bevacizumab versus sunitinib in treatment-naive metastatic renal cell carcinoma","volume":"26","author":"Atkins","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102862_b0190","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105815","article-title":"Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048","volume":"128","author":"Rischin","year":"2022","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102862_b0200","doi-asserted-by":"crossref","first-page":"e224427","DOI":"10.1001\/jamanetworkopen.2022.4427","article-title":"Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0205","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102862_b0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/oncolo\/oyae003","article-title":"The relationship between health-related quality of life and overall survival in patients with advanced renal cell carcinoma in CheckMate 214","volume":"29","author":"Cella","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jnci\/djad240","article-title":"Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355","volume":"116","author":"Cescon","year":"2024","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102862_b0220","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/djae129","article-title":"Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study","volume":"116","author":"Dent","year":"2024","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102862_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7464","article-title":"Quality of life and patient\u2010reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy","volume":"13","author":"Hoogland","year":"2024","journal-title":"Cancer Med"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102862_b0230","doi-asserted-by":"crossref","first-page":"e7360","DOI":"10.1002\/cam4.7360","article-title":"Health\u2010related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial","volume":"13","author":"Peris","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102862_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","author":"Sangro","year":"2024","journal-title":"J Clin Oncol Published online"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102862_b0240","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11136-023-03427-9","article-title":"Health-state utilities in long-term advanced melanoma survivors comparable with the general population","volume":"32","author":"Egeler","year":"2023","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ctrv.2024.102862_b0245","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s11136-020-02520-7","article-title":"Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings","volume":"29","author":"Joseph","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ctrv.2024.102862_b0250","first-page":"3267","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0255","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2192480","article-title":"Neurocognitive function, psychosocial outcome, and health\u2010related quality of life of the first\u2010generation metastatic melanoma survivors treated with ipilimumab","volume":"2020","author":"Rogiers","year":"2020","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102862_b0260","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.cllc.2020.09.014","article-title":"Patient-reported outcome measures used in routine care predict for survival at disease progression in patients with advanced lung cancer","volume":"22","author":"Friis","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102862_b0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2022.12.017","article-title":"Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age","volume":"176","author":"Suazo-Zepeda","year":"2023","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102862_b0270","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hed.27388","article-title":"Patient\u2010reported outcomes in immunotherapy for head and neck cancer","volume":"45","author":"Kirtane","year":"2023","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0280","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000526962","article-title":"Prospective evaluation of health-related quality of life in patients with metastatic urothelial carcinoma undergoing immunotherapy with pembrolizumab: symptom burden can predict survival","volume":"107","author":"Schneidewind","year":"2023","journal-title":"Urol Int"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102862_b0285","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/cam4.2958","article-title":"Patient reported symptoms associated with quality of life during chemo\u2010or immunotherapy for bladder cancer patients with advanced disease","volume":"9","author":"Taarnh\u00f8j","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102862_b0290","doi-asserted-by":"crossref","first-page":"e6293","DOI":"10.1002\/pon.6293","article-title":"Associations between age and patient\u2010reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors","volume":"33","author":"Fleszar-Pavlovic","year":"2024","journal-title":"Psychooncology"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101777","article-title":"Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: the ELDERS study","volume":"15","author":"Gomes","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102862_b0300","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000536332","article-title":"Quality of life impact in patients with cutaneous toxicities caused by epidermal growth factor receptor inhibitors and immunotherapy","volume":"240","author":"Mannino","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102862_b0305","first-page":"330","article-title":"Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study","volume":"32","author":"Tometich","year":"2024","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102862_b0310","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","article-title":"The experience of financial toxicity among advanced melanoma patients treated with immunotherapy","volume":"39","author":"Thom","year":"2021","journal-title":"J Psychosoc Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102862_b0315","article-title":"Investigating the quality of life for cancer patients and estimating the cost of immunotherapy in selected cases","volume":"14","author":"Fragkiadakis","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102862_b0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cllc.2019.11.015","article-title":"Patient-reported outcomes from patients receiving immunotherapy or chemoimmunotherapy for metastatic non\u2013small-cell lung cancer in clinical practice","volume":"21","author":"McLouth","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102862_b0325","article-title":"Quality of life in cancer patients receiving chemotherapy vs immunotherapy in tertiary hospital settings","volume":"16","author":"Mahtook","year":"2022","journal-title":"Onkologia i Radioterapia"},{"key":"10.1016\/j.ctrv.2024.102862_b0330","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100588","article-title":"Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment","volume":"7","author":"Aamdal","year":"2022","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102862_b0340","article-title":"Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab. International Journal of Gynecologic","volume":"32","author":"Kristeleit","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102862_b0345","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.lungcan.2024.107843","author":"Amari","year":"2024","journal-title":"Lung Cancer Published online"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0355","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.7150\/jca.49174","article-title":"Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: a systematic review","volume":"12","author":"Ma","year":"2021","journal-title":"J Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102862_b0360","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2217\/imt-2020-0103","article-title":"Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis","volume":"12","author":"Park","year":"2020","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102862_b0365","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0370","article-title":"Financial toxicity of cancer care: it\u2019s time to intervene","volume":"108","author":"Yousuf","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102862_b0375","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1023\/A:1008305523548","article-title":"The challenge of response shift for quality-of-life-based clinical oncology research","volume":"10","author":"Sprangers","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0385","first-page":"1","article-title":"Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measures","author":"Sawatzky","year":"2021","journal-title":"Qual Life Res Published online"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102862_b0395","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.3390\/curroncol29050251","article-title":"Patient-reported outcomes measurement in radiation oncology: interpretation of individual scores and change over time in clinical practice","volume":"29","author":"Kwon","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102862_b0400","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102862_b0405","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","article-title":"Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients","volume":"45","author":"Pickard","year":"2007","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102862_b0410","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/cncr.33457","article-title":"Health\u2010related quality\u2010of\u2010life assessment of patients with solid tumors on immuno\u2010oncology therapies","volume":"127","author":"Voon","year":"2021","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102862_b0420","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102862_b0425","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1634\/theoncologist.2018-0449","article-title":"Patient\u2010reported outcomes with PD\u20101\/PD\u2010L1 inhibitors for advanced cancer: a meta\u2010analysis","volume":"24","author":"Nishijima","year":"2019","journal-title":"Oncologist"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T03:03:28Z","timestamp":1763521408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":80,"alternative-id":["S0305737224001919"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102862","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102862"}}